drugset / Trial / NCT01185223

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation

NCT01185223

RandomizedParallel-groupOpen-labelPrevention

Summary

The objective of this study is to assess the efficacy and safety of oral valganciclovir versus intravenous ganciclovir in patients following allogenic stem cell transplantation.

Timeline

Start
2010-09
Primary completion
2012-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganciclovir Small molecule 5 mg/kg Intravenous
Subject Valganciclovir Small molecule 450 mg Oral